Procalcitonin and C-reactive protein as early markers of anastomotic leakage in intestinal resections for advanced ovarian cancer (EDMOCS).

Fecha de publicación: 01/07/2024 Fecha Ahead of Print: 26/03/2024

Autores de IIS La Fe

Víctor Lago Leal

Autor
Santiago Domingo Del Pozo

Autor

Participantes ajenos a IIS La Fe

Sánchez-Iglesias JL
Morales-Coma C
Minig L
Mancebo G
Siegrist J
Fidalgo García MS
Llueca A
Serra A
Cobas Lozano P
Lekuona Artola A
Gómez-Hidalgo NR
Acosta Ú
Ferrer-Costa R
Bradbury M
Pérez-Benavente A
Gil-Moreno A
SEGO Spain-GOG Group

Grupos

Medicina Reproductiva

Investigador Principal

José Morales Roselló

Abstract

INTRODUCTION: Serum levels of procalcitonin and C-reactive protein (CRP) have been used to predict anastomotic leakage after colorectal surgery, but information is scarce in advanced ovarian cancer (AOC) surgery with bowel resection. This study aimed to assess the predictive value of procalcitonin and CRP in detecting anastomotic leakage after AOC surgery with bowel resection. The study also aimed to determine the optimal postoperative reference values and the best day for evaluating these markers. MATERIAL AND METHODS: This prospective, observational and multicentric trial included 92 patients with AOC undergoing debulking surgery with bowel resection between 2017 and 2020 in 10 reference hospitals in Spain. Procalcitonin and CRP levels were measured at baseline and on postoperative days 1-6. Receiver operating characteristic analysis was performed to evaluate the predictive value of procalcitonin and CRP at each postoperative day. Sensitivity, specificity, positive and negative predictive values were calculated. RESULTS: Anastomotic leakage was detected in six patients (6.5%). Procalcitonin and CRP values were consistently higher in patients with anastomotic leakage at all postoperative days. The maximum area under the curve (AUC) for procalcitonin was observed at postoperative day 1 (AUC = 0.823) with a cutoff value of 3.8 ng/mL (83.3% sensitivity, 81.3% specificity). For CRP, the maximum AUC was found at postoperative day 3 (AUC = 0.833) with a cutoff level of 30.5 mg/dL (100% sensitivity, 80.4% specificity). CONCLUSIONS: Procalcitonin and C-reactive protein are potential biomarkers for early detection of anastomotic leakage after ovarian cancer surgery with bowel resection. Further prospective studies with a larger sample size are needed to confirm these findings.

Datos de la publicación

ISSN/ISSNe:: 0001-6349, 1600-0412
Tipo:: Article
Páginas:: 1302-1310
DOI:: 10.1111/aogs.14834
PubMed:: 38532280
Factor de Impacto:: 1,232 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Sánchez-Iglesias JL:: Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Biomedical Research Group in Gynecology, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
Morales-Coma C:: Breast Pathology Unit, Vall d'Hebron University Hospital, Barcelona, Spain
Minig L:: Department of Gynecologic Oncology, IMED Hospital, Valencia, Spain

Department of Gynecology, CEU Cardenal Herrera University, Valencia, Spain
Lago V:: Department of Gynecology, CEU Cardenal Herrera University, Valencia, Spain

Department of Gynecologic Oncology, La Fe University Hospital, Valencia, Spain
Domingo S:: Department of Gynecologic Oncology, La Fe University Hospital, Valencia, Spain
Mancebo G:: Gynecological Cancer Multidisciplinary Unit, Hospital del Mar, Barcelona, Spain

Department of Gynecology, Universitat Pompeu Fabra, Barcelona, Spain
Siegrist J:: Oncologic Gynecology Unit, Department of Gynecology, La Paz University Hospital, Madrid, Spain
Fidalgo García MS:: Department of Gynecologic Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
Llueca A:: Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery, Hospital General Universitario de Castellon, Castellón, Spain

Department of Medicine, Universidad Jaume I, Castellón, Spain
Serra A:: Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery, Hospital General Universitario de Castellon, Castellón, Spain

Department of Medicine, Universidad Jaume I, Castellón, Spain
Cobas Lozano P:: Department of Gynecologic Oncology, Hospital Universitario Donostia, OSI Donostialde, Donostia, Spain
Lekuona Artola A:: Department of Gynecologic Oncology, Hospital Universitario Donostia, OSI Donostialde, Donostia, Spain
Gómez-Hidalgo NR:: Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
Acosta Ú:: Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
Ferrer-Costa R:: Department of Biochemistry, Vall d'Hebron University Hospital, Barcelona, Spain
Bradbury M:: Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
Pérez-Benavente A:: Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Biomedical Research Group in Gynecology, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
Gil-Moreno A:: Department of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Biomedical Research Group in Gynecology, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain